Literature DB >> 12489282

Cancer prevention in patients with inflammatory bowel disease.

Steven H Itzkowitz1.   

Abstract

Colorectal cancer is an important, and often dreaded, consequence of long-standing UC and Crohn's colitis. Surveillance colonoscopy, despite its limitations, is beneficial for detecting earlier stage cancers and, probably, mortality reduction. Agents such as anti-inflammatory medications, folic acid, and ursodeoxycholic acid show promise for chemoprevention in this disease. Future research will help to define better the natural history of dysplasia in IBD, and to determine how molecular approaches may be integrated into surveillance programs to reduce CRC risk.

Entities:  

Mesh:

Year:  2002        PMID: 12489282     DOI: 10.1016/s0889-8553(02)00047-x

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  8 in total

Review 1.  New trends in molecular and cellular biomarker discovery for colorectal cancer.

Authors:  Parisa Aghagolzadeh; Ramin Radpour
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

Review 2.  5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease.

Authors:  Yang Cheng; Pierre Desreumaux
Journal:  World J Gastroenterol       Date:  2005-01-21       Impact factor: 5.742

3.  Aberrant expression of maspin in idiopathic inflammatory bowel disease is associated with disease activity and neoplastic transformation.

Authors:  Dengfeng Cao; Robb E Wilentz; James L Abbruzzese; Linus Ho; Anirban Maitra
Journal:  Int J Gastrointest Cancer       Date:  2005

Review 4.  Inflammatory bowel disease in Ashkenazi Jews: implications for familial colorectal cancer.

Authors:  Henry T Lynch; Randall E Brand; Gershon Y Locker
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

Review 5.  Cancer in inflammatory bowel disease.

Authors:  Jianlin Xie; Steven H Itzkowitz
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

6.  Interleukin-6 and risk of colorectal cancer: results from the CLUE II cohort and a meta-analysis of prospective studies.

Authors:  Artemisia Kakourou; Charalampia Koutsioumpa; David S Lopez; Judith Hoffman-Bolton; Gary Bradwin; Nader Rifai; Kathy J Helzlsouer; Elizabeth A Platz; Konstantinos K Tsilidis
Journal:  Cancer Causes Control       Date:  2015-07-29       Impact factor: 2.506

7.  Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors.

Authors:  Masayuki Fukata; Yasmin Hernandez; Daisy Conduah; Jason Cohen; Anli Chen; Keith Breglio; Tyralee Goo; David Hsu; Ruliang Xu; Maria T Abreu
Journal:  Inflamm Bowel Dis       Date:  2009-07       Impact factor: 5.325

Review 8.  Biomarkers of Inflammation and Immune Function and Risk of Colorectal Cancer.

Authors:  Alicia Garcia-Anguita; Artemisia Kakourou; Konstantinos K Tsilidis
Journal:  Curr Colorectal Cancer Rep       Date:  2015
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.